Aldeyra Therapeutics Inc

NASDAQ:ALDX   3:59:56 PM EDT
2.77
-0.01 (-0.36%)
Other Pre-Announcement

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results

Published: 05/05/2022 11:25 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Reports First-quarter 2022 Financial Results and Recent Corporate Highlights.
Net Loss for the Three Months Ended March 31, 2022 Was $16.8 Million, Or $0.29 per Share.
Q1 Earnings per Share View $-0.32 -- Refinitiv Ibes Data (analyst estimates).
Results From Phase 3 Tranquility-2 Trial of Reproxalap in Dry Eye Disease Expected in Second Quarter of 2022.
Results From Phase 2 Clinical Trial of Oral Rasp Inhibitor Adx-629 in Ethanol Toxicity Expected in the Second Half of 2022.